Advanced

Term amniotic fluid : An unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications

Moraghebi, Roksana LU ; Kirkeby, Agnete LU ; Chaves, Patricia LU ; Rönn, Roger E. LU ; Sitnicka, Ewa LU ; Parmar, Malin LU ; Larsson, Marcus LU ; Herbst, Andreas LU and Woods, Niels Bjarne LU (2017) In Stem Cell Research and Therapy 8(1).
Abstract

Background: Mesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clinical and clinical cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modelling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low volumes of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection... (More)

Background: Mesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clinical and clinical cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modelling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low volumes of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming. Methods: Amniotic fluid was collected at term caesarean section deliveries using a closed catheter-based system. Following fluid processing, amniotic fluid was assessed for cellularity, MSC frequency, in-vitro proliferation, surface phenotype, differentiation, and gene expression characteristics. Cells were also reprogrammed to the pluripotent stem cell state and differentiated towards neural and haematopoietic lineages. Results: The average volume of term amniotic fluid collected was approximately 0.4 litres per donor, containing an average of 7 million viable mononuclear cells per litre, and a CFU-F content of 15 per 100,000 MNCs. Expanded CFU-F cultures showed similar surface phenotype, differentiation potential, and gene expression characteristics to MSCs isolated from traditional sources, and showed extensive expansion potential and rapid doubling times. Given the high proliferation rates of these neonatal source cells, we assessed them in a reprogramming application, where the derived induced pluripotent stem cells showed multigerm layer lineage differentiation potential. Conclusions: The potentially large donor base from caesarean section deliveries, the high yield of term amniotic fluid MSCs obtainable, the properties of the MSCs identified, and the suitability of the cells to be reprogrammed into the pluripotent state demonstrated these cells to be a promising and plentiful resource for further evaluation in bio-banking, cell therapy, disease modelling, and regenerative medicine applications.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Biobanking, Caesarean section deliveries, Cell-based therapy, Cellular reprogramming, Mesenchymal stromal cells, Pluripotency, Regenerative medicine, Term amniotic fluid
in
Stem Cell Research and Therapy
volume
8
issue
1
publisher
BioMed Central
external identifiers
  • scopus:85028324351
  • wos:000408367800001
ISSN
1757-6512
DOI
10.1186/s13287-017-0582-6
language
English
LU publication?
yes
id
0cdd47d5-cc0d-4e2b-9c79-d6319f86ce43
date added to LUP
2017-10-06 10:43:51
date last changed
2018-09-09 04:54:51
@article{0cdd47d5-cc0d-4e2b-9c79-d6319f86ce43,
  abstract     = {<p>Background: Mesenchymal stromal cells (MSCs) are currently being evaluated in numerous pre-clinical and clinical cell-based therapy studies. Furthermore, there is an increasing interest in exploring alternative uses of these cells in disease modelling, pharmaceutical screening, and regenerative medicine by applying reprogramming technologies. However, the limited availability of MSCs from various sources restricts their use. Term amniotic fluid has been proposed as an alternative source of MSCs. Previously, only low volumes of term fluid and its cellular constituents have been collected, and current knowledge of the MSCs derived from this fluid is limited. In this study, we collected amniotic fluid at term using a novel collection system and evaluated amniotic fluid MSC content and their characteristics, including their feasibility to undergo cellular reprogramming. Methods: Amniotic fluid was collected at term caesarean section deliveries using a closed catheter-based system. Following fluid processing, amniotic fluid was assessed for cellularity, MSC frequency, in-vitro proliferation, surface phenotype, differentiation, and gene expression characteristics. Cells were also reprogrammed to the pluripotent stem cell state and differentiated towards neural and haematopoietic lineages. Results: The average volume of term amniotic fluid collected was approximately 0.4 litres per donor, containing an average of 7 million viable mononuclear cells per litre, and a CFU-F content of 15 per 100,000 MNCs. Expanded CFU-F cultures showed similar surface phenotype, differentiation potential, and gene expression characteristics to MSCs isolated from traditional sources, and showed extensive expansion potential and rapid doubling times. Given the high proliferation rates of these neonatal source cells, we assessed them in a reprogramming application, where the derived induced pluripotent stem cells showed multigerm layer lineage differentiation potential. Conclusions: The potentially large donor base from caesarean section deliveries, the high yield of term amniotic fluid MSCs obtainable, the properties of the MSCs identified, and the suitability of the cells to be reprogrammed into the pluripotent state demonstrated these cells to be a promising and plentiful resource for further evaluation in bio-banking, cell therapy, disease modelling, and regenerative medicine applications.</p>},
  articleno    = {190},
  author       = {Moraghebi, Roksana and Kirkeby, Agnete and Chaves, Patricia and Rönn, Roger E. and Sitnicka, Ewa and Parmar, Malin and Larsson, Marcus and Herbst, Andreas and Woods, Niels Bjarne},
  issn         = {1757-6512},
  keyword      = {Biobanking,Caesarean section deliveries,Cell-based therapy,Cellular reprogramming,Mesenchymal stromal cells,Pluripotency,Regenerative medicine,Term amniotic fluid},
  language     = {eng},
  month        = {08},
  number       = {1},
  publisher    = {BioMed Central},
  series       = {Stem Cell Research and Therapy},
  title        = {Term amniotic fluid : An unexploited reserve of mesenchymal stromal cells for reprogramming and potential cell therapy applications},
  url          = {http://dx.doi.org/10.1186/s13287-017-0582-6},
  volume       = {8},
  year         = {2017},
}